All In Vivo Testing articles – Page 8
-
NewsDNA repair genes drive Huntington's disease, UCLA study finds
A new UCLA study reveals that DNA mismatch repair genes play a crucial role in Huntington’s disease by driving neuronal damage and motor impairments. Targeting these genes, especially Msh3 and Pms1, could offer promising therapeutic avenues for the disease.
-
NewsThe immune cells that fuel food allergies
A new study reveals how specific immune cells contribute to the exaggerated immune response in food allergies, offering hope for improved treatments in the future.
-
NewsTessera's gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
-
News
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
-
ArticleInitial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy ...
-
NewsDamaged small intestine repaired with hPSC-derived organoids
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
-
ArticleA novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates ...
-
NewsIdentifying disease-promoting microenvironments in AKI
The study’s findings could contribute to future therapeutic strategies to prevent chronic kidney disease.
-
NewsNew DNA aptamer stabilises atherosclerosis plaques
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
-
NewsEnhancing drug discovery using genetically diverse mouse models
Researchers suggest that integrating genetically diverse mouse models with cell-based assays will better replicate human diseases.
-
NewsDevelopment of a new and promising antimalarial agent
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
-
NewsNovel inhibitor developed to combat HER2-positive breast cancer
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
-
NewsMini-colons offer improved cellular diversity, longevity and function
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
-
ArticleTessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
As the industry looks beyond CRISPR to safely introduce therapeutic genomic changes anywhere in the body, in vivo gene editing holds immense potential to address diseases with a genetic basis. Boston-based biotech Tessera Therapeutics is pioneering the next generation of genetic medicines with its Gene Writing™ platform. At this year’s ...
-
NewsNew ENaC blocker demonstrates an extended duration of action
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
-
NewsNovel version of CRISPR gene-editing protein engineered
Researchers have developed a new, compact EbCas12a variant that can be packaged into an all-in-one AAV system with its crRNA.
-
NewsReprogramming immune-suppressive macrophages in tumours
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
-
ArticleEnhancing gene therapy with Circio
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy. ...
-
NewsOvarian cancer: CBR-5884 demonstrates promising antitumour effects
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.
-
NewsGene editing for HSV-1 shows significant reduction of viral load
The experimental therapy eliminated 90 percent of HSV-1 after facial infection and 97 percent of HSV-1 after genital infection.